Morphic Holding Revenue 2019-2021 | MORF

Morphic Holding revenue from 2019 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Morphic Holding Annual Revenue
(Millions of US $)
2020 $45
2019 $17
2018 $3
Morphic Holding Quarterly Revenue
(Millions of US $)
2021-06-30 $4
2021-03-31 $3
2020-12-31 $6
2020-09-30 $26
2020-06-30 $8
2020-03-31 $6
2019-12-31 $-0
2019-09-30 $6
2019-06-30 $6
2019-03-31 $6
2018-12-31
2018-09-30
2018-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.142B $0.045B
Morphic Holding Inc. is a biopharmaceutical company. It focuses on the discovery and development of oral small-molecule integrin therapeutics for autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer. Morphic Holding Inc. is based in Waltham, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00